Navigation Links
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in 100 countries.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patients Taking Nexavar

Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer

Nexavar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential are advised to avoid becoming pregnant and female patients should also be advised against breastfeeding while receiving Nexavar

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar

Uncommon but serious adverse reactions, including keratoacanthomas/squamous cell cancer of the skin and Stevens-Johnson Syndrome, have been reported in clinical trials

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adve
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... One of the major trends in the market ... useful in different application sectors such as hard tissue ... forecast the Global Bioactive Material Market to ... period 2013-2018. According to the report, increase in aging ... market. There will be an increased number of trauma, ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered ... Well-Being Coach Christi Hall to campus. , Hall’s journey to ... and gaining weight as a result of years of medication. ... about nutrition. One year later she had lost 50 pounds, ... endurance and cardio. , After joining the YMCA staff, she ...
(Date:9/19/2014)... There are thousands of older women who ... and there are thousands of younger men who would love ... SeekingCougar.com now provides the world's best collection of resources ... older women, and the younger men who would like to ... these people to meet each other and establish those romantic ...
(Date:9/18/2014)... Thompson and Mathieu Nikel decided it was time to tie the ... Isaac, said there was only one choice for them – Mercy ... Thompson was an undergraduate student and needed a French tutor. She ... French and so she asked him. , Thompson is ... was 7 years old. Nikel is originally from France came ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a ... of Facial Plastic and Reconstructive Surgery and a Professor ... Facial Plastic Surgery. He is recognized around the ... , Dr. Ellis will be presenting on numerous injectable ... injection techniques and various treatments for complications associated with ...
Breaking Medicine News(10 mins):Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 2Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 3Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 4Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... Oct. 17 Symmetry Medical Inc.,(NYSE: SMA ... global orthopedic,device industry and other medical markets, announced ... Officer, Europe effective November 1,2007. Mr. Hynes ... case facilities across Europe including the UK, Ireland,France ...
... against the facial paralysis, study finds , , WEDNESDAY, Oct. 17 ... at easing a form of facial paralysis called Bell,s palsy ... that acyclovir may not be a new, improved treatment option ... the other hand, many people afflicted with Bell,s palsy do ...
... receive failing grades , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... to women,s health, a new report contends. , The report ... meets only three of 27 benchmarks for women,s health. Those ... who get regular mammograms; the percentage of women who visit ...
... Include New Research on HIV Screening, Pandemic Flu,Neonatal ... WASHINGTON, Oct. 17 More than 13,000 public,health ... to address the,nation,s top public health challenges at ... The conference will feature leading experts, researchers ...
... Oct. 17 Two health care leaders were,presented ... (MHA),Health Care Leadership Award. Terence F. Moore, president ... the award in the,category of hospital management and ... with the award in the category of patient ...
... Lumenos suite of products helps consumers manage costs and adopt healthier ... ... Anthem Blue Cross and Blue,Shield in Virginia is now offering new health ... about health,care-helping them to lead healthier lives and gain control over the ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:Antiviral Won't Improve Bell's Palsy Outcome 2Health News:U.S. Women's Health Care Still Falls Short: Report 2Health News:U.S. Women's Health Care Still Falls Short: Report 3Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Nov. 3-7 2Health News:Association Honors Health Care Leaders in Midland and Troy 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 3Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 4
... The Infinity AST (GOT) powder reagent ... convenience of single liquid stability to help ... provide quick result turnaround time. The patented ... reagent provides a long shelf life and ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: